For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

Scientist

OUR TECHNOLOGY

Harnessing the Power of the Immune System

Our industry-leading cell therapy technology uses the power of a person's own immune system to target and attack their tumors. This is accomplished through the use of genetically modified T cells that can increase the number of tumor-specific T cells and strengthen the body’s ability to kill certain types of cancer cells.

We believe cell therapy has the power to transform cancer care, so we’re pursuing all potential avenues to help bring it to those who need it.

Our T Cell Therapy Process in Action

  • Collect Icon

    COLLECT patient's white blood cells

  • Isolate Icon

    Isolate and activate T cells

  • Engineer Icon

    Engineer T cells with CAR or TCR gene

  • Grow Icon

    Grow and expand number of T cells

  • Infuse Icon

    Infuse same patient with engineered T cells

Cell Therapy Platforms

We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to address both hematological cancers and solid tumors.

Chimeric Antigen Receptor (CAR) Explained

CARs are modified proteins composed of two distinct functional components. The first consists of an antibody fragment or target binding domain that allows CARs to recognize targets that are present on the surface of cancer cells. The second provides signals that are designed to rapidly and powerfully activate the T cell to attack cancer cells. We are developing multiple CAR product candidates, including axicabtagene ciloleucel and KTE-X19, while continuing to innovate the next generation of CAR-engineered T cells.

Graphic Car T agains Cancer cell

T Cell Receptor (TCR) Explained

TCRs are proteins that allow T cells to identify and destroy tumors by recognizing specific fragments of cancer cells displayed on their surface. Following leukapheresis, T cells are genetically modified with a TCR gene, and the engineered TCR T cells have the ability to recognize and attack various types of tumor cells. Kite, in collaboration with its partners, is currently advancing several TCR programs that target cancer-specific proteins, such as cancer/testis antigens, viral antigens, and neoantigens.

TCR therapy is investigational, and its safety and efficacy have not been established.

Graphic TCR T Cell agains Cancer cell

Therapies iconOur Therapies

We have an unwavering commitment to developing and gaining approval for innovative therapies. Our focus is on providing therapeutic options that healthcare providers can use to make a difference in the lives of their patients.